Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of Evobrutinib vs Teriflunomide in relapsing multiple sclerosis
2019-004972-20Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Annualized relapse rate (ARR) based on qualified relapses up to 156 weeks. Started May 2020; status: terminated.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-004972-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004972-20.